Test Price
2,800 AED✅ Home Collection Available
FGF23 Gene, Autosomal Dominant Hypophosphatemic Rickets – Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين FGF23 للكشف عن كساح نقص فوسفات الدم الوراثي السائد في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary / ملخص تنفيذي
This advanced genetic test delivers definitive diagnosis of autosomal dominant hypophosphatemic rickets (ADHR) through targeted NGS of the FGF23 gene, enabling precise clinical management and family risk assessment. Our ISO‑certified laboratory combines 99.9% diagnostic sensitivity with full UAE regulatory compliance, including home collection and post‑test genetic counselling.
يوفر هذا الفحص الجيني المتقدم تشخيصًا قاطعًا لكساح نقص فوسفات الدم الوراثي السائد من خلال التسلسل الجيني المستهدف لجين FGF23، مما يتيح إدارة سريرية دقيقة وتقييمًا للمخاطر العائلية. يجمع مختبرنا الحاصل على شهادة ISO بين حساسية تشخيصية تبلغ 99.9% والامتثال الكامل للوائح دولة الإمارات، بما في ذلك خدمة السحب المنزلي والاستشارة الوراثية بعد الفحص.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain Home Collection and VIP Mobile Phlebotomy.
Clinical Guidance: Telephonic Post‑Test Clinical Guidance for result interpretation by a DHA‑licensed genetic counsellor.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
1. Test Overview & Methodology Comparison
The FGF23 Next‑Generation Sequencing (NGS) test analyses the entire coding region of the FGF23 gene to detect pathogenic variants responsible for autosomal dominant hypophosphatemic rickets. This rare disorder causes renal phosphate wasting, leading to rickets, bone pain, and growth retardation. Our test offers a definitive molecular diagnosis, distinguishing ADHR from other hypophosphatemic conditions, and supports accurate genetic counselling.
| Feature | Our Test – FGF23 NGS | Closest Alternative – Whole Exome Sequencing |
|---|---|---|
| Precision | Targeted deep coverage (>100×) for FGF23; includes splice‑site analysis | Broad coverage, variable depth; may require additional Sanger confirmation |
| Methodology | NGS with Sanger validation of all detected variants | NGS only; validation performed only for selected variants |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Clinical Report | ACMG‑compliant interpretation, family risk assessment, and genetic counselling note | Generic report with secondary findings; often requires re‑analysis by a specialist |
| Price (AED) | 2800 | 5500–7200 |
| DHA Accreditation | Yes (Facility License 9834453) | Varies by provider |
2. Physician Insight & Safety Protocol
"As a clinician, I want families to understand that this genetic test is not a standalone screening tool; it must be interpreted alongside serum phosphate, FGF23 levels, and renal tubular function. A positive result confirms ADHR and allows targeted therapy and informed reproductive choices, but clinical outcomes depend on early intervention and lifelong monitoring. My team and I ensure that every report is accompanied by a thorough post‑test counselling session to address your concerns."
— Dr. PRABHAKAR REDDY, DHA License 61713011, Senior Consultant in Genetic Medicine & Metabolic Bone Disorders
Medication Warning
⚠ Do not discontinue prescribed phosphate supplements, active vitamin D, or calcitriol without consulting your physician. The test result guides therapy adjustment but does not replace ongoing medical care.
Safety Exclusion Criteria & Red Flags
- Exclusion: Active fever (>38.5°C), recent blood transfusion (within 4 weeks), or inability to provide informed consent (guardian required for minors).
- Home Collection Refusal: If the patient is unable to maintain stable venous access or has a history of severe needle phobia, phlebotomy may be rescheduled at a clinical facility.
- Red Flags – Seek Immediate ER Care: Acute bone pain with swelling or deformity, inability to bear weight, new‑onset seizures (hypocalcemia), or severe muscle weakness – these may indicate metabolic decompensation unrelated to the gene test result.
3. Frequently Asked Questions & Clinical Guidance
What is the FGF23 gene test and why is it recommended?
The FGF23 gene test is a targeted next‑generation sequencing assay that detects mutations in the FGF23 gene responsible for autosomal dominant hypophosphatemic rickets, enabling a definitive diagnosis and guiding lifelong phosphate management and genetic counselling. In the UAE, it is particularly valuable for families with a history of early‑onset rickets or unexplained bone deformities, as it differentiates ADHR from other hereditary hypophosphatemias and avoids unnecessary vitamin D toxicity.
تحليل جين FGF23 هو فحص جزيئي متقدم يستخدم التسلسل الجيني عالي الإنتاجية للكشف عن الطفرات المسببة لكساح نقص فوسفات الدم الوراثي السائد، مما يتيح تشخيصًا قاطعًا وتوجيهًا دقيقًا للعلاج ووراثة المرض.
How is the sample collected and how long do results take?
A single drop of blood on an FTA card, extracted DNA, or 3 mL of whole blood in an EDTA tube is collected, and results are reported within 3 to 4 weeks via a secure patient portal with an optional telephonic interpretation by a DHA-licensed genetic counsellor. Home collection ensures minimal discomfort and strict cold‑chain maintenance, while the laboratory processes the sample using ISO 9001:2015‑compliant NGS technology.
يتم جمع العينة بقطرة دم واحدة على بطاقة FTA أو 3 مل من الدم الكامل في أنبوب EDTA، وتصدر النتائج خلال 3 إلى 4 أسابيع عبر بوابة إلكترونية آمنة مع إمكانية التفسير الهاتفي من قبل مستشار وراثي مرخص من هيئة الصحة بدبي.
Is this covered by UAE health insurance, and are minors eligible?
Coverage varies by policy, but many UAE insurers now reimburse targeted genetic testing when pre‑authorised, and minors can be tested with mandatory parental consent under the 2026 CDS Law after an in‑person genetic counselling session. Our team assists with direct billing verification and provides the required pre‑authorisation forms, ensuring full compliance with Federal Decree‑Law No. 41 of 2024 on medical advertising and UAE Personal Data Protection Law.
تغطية التأمين تختلف حسب البوليصة، لكن العديد من شركات التأمين في الإمارات تعوض الفحوصات الجينية المستهدفة بعد الموافقة المسبقة، ويمكن إجراء الفحص للقاصرين بموافقة الوالدين وفقًا لقانون البيانات الصحية لعام 2026.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians